[1]莫伟嘉,唐宇星,宋 畅,等.PSMD6在肝细胞癌中的异常高表达及临床价值[J].医学信息,2024,37(18):1-5.[doi:10.3969/j.issn.1006-1959.2024.18.001]
　MO Wei-jia,TANG Yu-xing,SONG Chang,et al.Abnormal High Expression and its Clinical Value of PSMD6 in Hepatocellular Carcinoma[J].Journal of Medical Information,2024,37(18):1-5.[doi:10.3969/j.issn.1006-1959.2024.18.001]
点击复制

PSMD6在肝细胞癌中的异常高表达及临床价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年18期
页码:
1-5
栏目:
生物信息学
出版日期:
2024-09-15

文章信息/Info

Title:
Abnormal High Expression and its Clinical Value of PSMD6 in Hepatocellular Carcinoma
文章编号:
1006-1959（2024）18-0001-05
作者:
莫伟嘉1; 唐宇星1; 宋 畅1; 黄庆玲1; 赵春艳1; 罗嘉嫄1; 蒋洪棉2; 陈 罡1; 吴华裕3
1.广西医科大学第一附属医院病理科，广西 南宁 530021；2.南宁市第一人民医院病理科，广西 南宁 530022；3.南宁市第一人民医院医学实验中心，广西 南宁 530022
Author(s):
MO Wei-jia1; TANG Yu-xing1; SONG Chang1; HUANG Qing-ling1; ZHAO Chun-yan1; LUO Jia-yuan1; JIANG Hong-mian2; CHEN Gang1; WU Hua-yu3
1.Department of Pathology,the First Affiliated Hospital of Guangxi Medical University,Nanning 530021,Guangxi,China;2.Department of Pathology,the First People’s Hospital of Nanning,Nanning 530022,Guangxi,China; 3.Medical Experimental Center,the First People’s Hospital of Nanning,Nanning 530022,Guangxi,China
关键词:
PSMD6; 肝细胞癌; 上皮-间叶细胞转化
Keywords:
PSMD6; Hepatocellular carcinoma; Epithelial-mesenchymal cell transformation
分类号:
R735.7
DOI:
10.3969/j.issn.1006-1959.2024.18.001
文献标志码:
A
摘要:
目的 评估PSMD6在肝细胞癌（HCC）患者组织中的表达情况，并探究其潜在临床价值。方法 基于Gene Expression Omnibus（GEO）、Metabric、TCGA-GTEx、ArrayExpress、Sequence Read Archive（SRA）数据库，综合分析全球多中心、多平台的PSMD6基因表达谱，探究PSMD6的mRNA在HCC中的过表达趋势。同时，使用The Human Protein Atlas组织芯片库展示PSMD6在HCC组织中蛋白表达情况。绘制KM曲线，分析PSMD6在HCC中的预后预测价值。结果 PSMD6蛋白表达的阳性染色信号定位于HCC细胞的细胞浆和核膜中，表达强度中等，染色度中等。HCC中PSMD6高表达（P＜0.01），结果未发生偏倚。SROC的AUC为0.75（0.71，0.79），敏感性为0.64，特异性为0.74，提示PSMD6具有中度鉴别HCC的能力。生存分析显示，PSMD6高表达的患者面临着更高的生存风险（HR=1.4，P=0.043）。结论 PSMD6在HCC中异常高表达，可作为HCC筛查和治疗潜在靶点。
Abstract:
Objective To evaluate the expression of PSMD6 in patients with hepatocellular carcinoma (HCC), and explore its potential clinical value.Methods Based on Gene Expression Omnibus (GEO), Metabric, TCGA-GTEx, ArrayExpress, Sequence Read Archive (SRA) databases, the global multi-center and multi-platform PSMD6 gene expression profiles were comprehensively analyzed to explore the overexpression trend of PSMD6 mRNA in HCC. At the same time, the Human Protein Atlas tissue microarray library was used to show the protein expression of PSMD6 in HCC tissues. KM curve was drawn to analyze the prognostic value of PSMD6 in HCC.Results The positive staining signal of PSMD6 protein expression was located in the cytoplasm and nuclear membrane of HCC cells, with moderate expression intensity and moderate staining degree. PSMD6 was highly expressed in HCC (P<0.01), and the results were not biased. The AUC of SROC was 0.75 (0.71, 0.79), the sensitivity was 0.64, and the specificity was 0.74, suggesting that PSMD6 had a moderate ability to identify HCC. Survival analysis showed that patients with high expression of PSMD6 with a higher survival risk (HR=1.4, P=0.043).Conclusion PSMD6 is abnormally highly expressed in HCC, which can be used as a potential target for HCC screening and treatment.

参考文献/References:

[1]Chakraborty E,Sarkar D.Emerging Therapies for Hepatocellular Carcinoma (HCC)[J].Cancers (Basel),2022,14(11):2798.[2]Siegel RL,Miller KD,Wagle NS,et al.Cancer statistics,2023[J].CA Cancer J Clin,2023,73(1):17-48.[3]Shi JF,Cao M,Wang Y,et al.Is it possible to halve the incidence of liver cancer in China by 2050?[J].Int J Cancer,2021,148(5):1051-1065.[4]Zhou H,Song T.Conversion therapy and maintenance therapy for primary hepatocellular carcinoma[J].Biosci Trends,2021,15(3):155-160.[5]Raja A,Haq F.Molecular classification of hepatocellular carcinoma:prognostic importance and clinical applications[J].J Cancer Res Clin Oncol,2022,148(1):15-29.[6]Gao YX,Yang TW,Yin JM,et al.Progress and prospects of biomarkers in primary liver cancer (Review)[J].Int J Oncol,2020,57(1):54-66.[7]Li X,Li X,Hu Y,et al.PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer:based on bioinformatics analysis and in vitro validation[J].BMC Cancer,2023,23(1):573.[8]Devoy A,Soane T,Welchman R,et al.The ubiquitin-proteasome system and cancer[J].Essays Biochem,2005,41:187-203.[9]Bard JAM,Goodall EA,Greene ER,et al.Structure and Function of the 26S Proteasome[J].Annu Rev Biochem,2018,87:697-724.[10]Xuan DTM,Wu CC,Kao TJ,et al.Prognostic and immune infiltration signatures of proteasome 26S subunit,non-ATPase (PSMD) family genes in breast cancer patients[J].Aging (Albany NY),2021,13(22):24882-24913.[11]Okumura T,Ikeda K,Ujihira T,et al.Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation[J].J Biochem,2018,163(1):19-29.[12]Rubio AJ,Bencomo-Alvarez AE,Young JE,et al.26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy[J].Cells,2021,10(9):2390.[13]Zhang C,Xu T,Ji K,et al.An integrative analysis reveals the prognostic value and potential functions of PSMD11 in hepatocellular carcinoma[J].Mol Carcinog,2023,62(9):1355-1368.[14]Huang W,Mei J,Liu YJ,et al.An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC)[J].J Hepatocell Carcinoma,2023,10:497-515.[15]Tsolou A,Nelson G,Trachana V,et al.The 19S proteasome subunit Rpn7 stabilizes DNA damage foci upon genotoxic insult[J].IUBMB Life,2012,64(5):432-442.[16]Lv J,Zhang S,Wu H,et al.Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2[J].Cancer Lett,2020,469:22-34.[17]Liu F,Lou K,Zhao X,et al.miR-214 regulates papillary thyroid carcinoma cell proliferation and metastasis by targeting PSMD10[J].Int J Mol Med,2018,42(6):3027-3036.[18]Schlosser S,Tümen D,Volz B,et al.HCC biomarkers - state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice[J].Front Oncol,2022,12:1016952.[19]Tanaka K.The proteasome:overview of structure and functions[J].Proc Jpn Acad Ser B Phys Biol Sci,2009,85(1):12-36.[20]Fernando LM,Quesada-Candela C,Murray M,et al.Proteasomal subunit depletions differentially affect germline integrity in C.elegans[J].Front Cell Dev Biol,2022,10:901320.

相似文献/References:

[1]王利娜,赵雪梅,徐云霞,等.磁共振扩散张量成像在肝细胞癌及 肝转移瘤鉴别诊断价值研究[J].医学信息,2018,31(09):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
　WANG Li-na,ZHAO Xue-mei,XU Yun-xia,et al.Diagnostic Value of Magnetic Resonance Diffusion Tensor Imaging in Hepatocellular Carcinoma and Liver Metastases[J].Journal of Medical Information,2018,31(18):12.[doi:10.3969/j.issn.1006-1959.2018.09.004]
[2]刘 冰,杨 帅,费锡斌,等.GPC-3联合CK-19免疫组化检测在肝细胞癌诊断及鉴别诊断中的应用[J].医学信息,2019,32(23):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
　LIU Bing,YANG Shuai,FEI Xi-bin,et al.Application of GPC-3 Combined with CK-19 Immunohistochemical Detection in Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(18):169.[doi:10.3969/j.issn.1006-1959.2019.23.054]
[3]刘丽丽.CLCVP对肝细胞癌行腹腔镜肝叶切除手术相关指标及肝门阻断时间的影响[J].医学信息,2020,33(19):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
　LIU Li-li.The Effect of CLCVP on the Operation-related Indexes and Port Occlusion Time in Patients with Hepatocellular Carcinoma Undergoing Laparoscopic Lobectomy[J].Journal of Medical Information,2020,33(18):88.[doi:10.3969/j.issn.1006-1959.2020.19.025]
[4]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
　SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Journal of Medical Information,2021,34(18):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
[5]林思其,张泽鑫,夏睿琪,等.三种miRNA对肝癌预后预测的生物信息学分析模型[J].医学信息,2022,35(03):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]
　LIN Si-qi,ZHANG Ze-xin,XIA Rui-qi,et al.A Model of Three miRNA on the Prognosis Prediction of Hepatocellular Carcinomaby Bioinformatics Analysis[J].Journal of Medical Information,2022,35(18):81.[doi:10.3969/j.issn.1006-1959.2022.03.019]
[6]李一鸣,陈文翔,王 禹,等.肝癌预后模型的构建及其在免疫治疗中的作用研究[J].医学信息,2022,35(04):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
　LI Yi-ming,CHEN Wen-xiang,WANG Yu,et al.The Construction of a Prognostic Model for Hepatocellular Carcinomaand its Role in Immunotherapy[J].Journal of Medical Information,2022,35(18):68.[doi:10.3969/j.issn.1006-1959.2022.04.018]
[7]徐帅帅,高 斌.TACE与阿帕替尼联合治疗中晚期肝细胞癌的疗效及安全性分析[J].医学信息,2022,35(06):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
　XU Shuai-shuai,GAO Bin.Analysis of the Efficacy and Safety of TACE Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(18):116.[doi:10.3969/j.issn.1006-1959.2022.06.028]
[8]李文华,许传斌,崔景景,等.基于治疗前MR-T2WI影像组学特征预测肝细胞癌射频消融术后早期复发的价值[J].医学信息,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
　LI Wen-hua,XU Chuan-bin,CUI Jing-jing,et al.The Value of Predicting Early Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Based on Pre-treatment MR-T2WI Radiomics Features[J].Journal of Medical Information,2022,35(18):39.[doi:10.3969/j.issn.1006-1959.2022.18.009]
[9]彭莉蓉,黎村艳,史 杨.肿瘤微环境免疫细胞中差异lncRNA对肝细胞癌预后的预测价值[J].医学信息,2022,35(20):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
　PENG Li-rong,LI Cun-yan,SHI Yang.The Predictive Value of Differential lncRNA in Tumor Microenvironment Immune Cells for the Prognosis of Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(18):18.[doi:10.3969/j.issn.1006-1959.2022.20.005]
[10]裴金仙,陈天狮,任巧晶,等.JAK2/STAT3通路在HBV相关肝细胞癌中表达及机制研究[J].医学信息,2022,35(24):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]
　PEI Jin-xian,CHEN Tian-shi,REN Qiao-jing,et al.The Expression and Mechanism of JAK2/STAT3 Pathway in HBV-related Hepatocellular Carcinoma[J].Journal of Medical Information,2022,35(18):59.[doi:10.3969/j.issn.1006-1959.2022.24.012]

更新日期/Last Update: 1900-01-01